Eyepoint Pharmaceuticals Inc (EYPT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Eyepoint Pharmaceuticals Inc (EYPT) has a cash flow conversion efficiency ratio of -0.297x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-59.35 Million) by net assets ($200.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Eyepoint Pharmaceuticals Inc balance sheet quality to measure how much of total assets are equity-financed.
Eyepoint Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2002–2024)
This chart illustrates how Eyepoint Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Eyepoint Pharmaceuticals Inc (EYPT) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Eyepoint Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eyepoint Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenzhen Laibao High-Technology Co Ltd
SHE:002106
|
0.017x |
|
Henan Yicheng New Energy Co Ltd
SHE:300080
|
-0.019x |
|
Chang Wah Electromaterials Inc
TW:8070
|
0.037x |
|
Revolve Group LLC
NYSE:RVLV
|
0.024x |
|
Teekay Corporation
NYSE:TK
|
0.140x |
|
Sichuan Haite High-tech Co Ltd
SHE:002023
|
0.002x |
|
Shenyang Toly Bread Co Ltd
SHG:603866
|
0.043x |
|
Shen Ma Industry Co Ltd
SHG:600810
|
0.024x |
Annual Cash Flow Conversion Efficiency for Eyepoint Pharmaceuticals Inc (2002–2024)
The table below shows the annual cash flow conversion efficiency of Eyepoint Pharmaceuticals Inc from 2002 to 2024. For the full company profile with market capitalisation and key ratios, see EYPT company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $336.50 Million | $-126.23 Million | -0.375x | -5428.07% |
| 2023-12-31 | $266.32 Million | $1.88 Million | 0.007x | +101.04% |
| 2022-12-31 | $96.37 Million | $-65.00 Million | -0.675x | -148.27% |
| 2021-12-31 | $184.38 Million | $-50.10 Million | -0.272x | +65.10% |
| 2020-12-31 | $18.54 Million | $-14.44 Million | -0.779x | +88.56% |
| 2019-12-31 | $8.33 Million | $-56.70 Million | -6.807x | -263.12% |
| 2018-12-31 | $11.69 Million | $-21.91 Million | -1.874x | -22.00% |
| 2017-12-31 | $13.34 Million | $-20.49 Million | -1.536x | -96.63% |
| 2016-12-31 | $20.88 Million | $-16.32 Million | -0.781x | -277.33% |
| 2015-12-31 | $23.37 Million | $10.30 Million | 0.441x | +161.63% |
| 2014-12-31 | $14.92 Million | $-10.67 Million | -0.715x | +37.04% |
| 2013-12-31 | $7.70 Million | $-8.74 Million | -1.136x | -72.05% |
| 2012-12-31 | $13.64 Million | $-9.00 Million | -0.660x | -679.47% |
| 2011-12-31 | $37.43 Million | $-3.17 Million | -0.085x | -128.27% |
| 2010-12-31 | $33.04 Million | $9.90 Million | 0.300x | +183.60% |
| 2009-12-31 | $23.54 Million | $-8.44 Million | -0.358x | -51.84% |
| 2008-12-31 | $21.79 Million | $-5.14 Million | -0.236x | +26.68% |
| 2007-12-31 | $65.91 Million | $-21.21 Million | -0.322x | -32.04% |
| 2006-12-31 | $66.20 Million | $-16.14 Million | -0.244x | -58.47% |
| 2005-12-31 | $60.74 Million | $-9.34 Million | -0.154x | 0.00% |
| 2004-12-31 | $60.74 Million | $-9.34 Million | -0.154x | +24.42% |
| 2003-12-31 | $26.70 Million | $-5.44 Million | -0.204x | +71.85% |
| 2002-12-31 | $4.23 Million | $-3.06 Million | -0.723x | -- |
About Eyepoint Pharmaceuticals Inc
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib… Read more